Table 2 Association between medicine retailer knowledge, behaviours and study outcomes
| Â | % (n) | Unadjusted odds ratios and (95% confidence intervals; p-values) | ||
|---|---|---|---|---|
Recommended ACTs as malaria treatment for adult patients | Recommended ACTs as malaria treatment for under 5 patients | Reported selling ACTs more than any other antimalarial | ||
Identified ACT as MOH-recommended antimalarial | ||||
 No | 37% (32) | 1 (reference) | 1 (reference) | 1 (reference) |
 Yes | 63% (55) | 3.0 (1.21–7.47; 0.018)** | 2.34 (0.93–5.88; 0.070)* | 2.36 (0.92–6.03; 0.073)* |
Recommended ACT to adults | ||||
 No | 45% (39) | – | 1 (reference) | 1 (reference) |
 Yes | 55% (48) | – | 5.37 (2.08–13.87; 0.001)** | 8.89 (3.11–25.39; < 0.001)** |
Recommended ACT to children | ||||
 No | 55% (48) | 1 (reference) | – | 1 (reference) |
 Yes | 45% (39) | 5.37 (2.08–13.87; 0.001)** | – | 3.76 (1.52–9.28; 0.004)** |
Sold ACTs more than any other antimalarial | ||||
 No | 59% (51) | 1 (reference) | 1 (reference) | – |
 Yes | 41% (36) | 8.89 (3.11–25.39; < 0.001)** | 3.76 (1.52–9.28; 0.004)** | – |
Gave Fansidar to a mother requesting it | ||||
 No | 81% (70) | 1 (reference) | 1 (reference) | 1 (reference) |
 Yes | 18% (16) | 0.67 (0.21–2.01; 0.461) | 0.36 (0.11–1.25; 0.109)* | 0.94 (0.30–2.94; 0.919) |